Because HDAC inhibitors are expected to act on transcription regulation, the modulation at the protein level in part reflected that of mRNA in tumors, as shown by TaqMan arrays; down-modulation of CCL2 was confirmed also in human melanoma cells (Supplementary Figure S4). This evidence concerns the gene HDAC9 and melanoma.